FY2025 EPS Estimates for Zoetis Decreased by Leerink Partnrs

Zoetis Inc. (NYSE:ZTS) – Research analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Zoetis in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $6.09 per share for the year, down from their previous forecast of $6.19. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.39 EPS, FY2025 earnings at $6.09 EPS, FY2026 earnings at $6.82 EPS, FY2027 earnings at $7.46 EPS, FY2027 earnings at $7.46 EPS, FY2028 earnings at $8.10 EPS and FY2028 earnings at $8.10 EPS.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%.

A number of other research firms have also commented on ZTS. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $214.90.

Zoetis Price Performance

Shares of Zoetis stock opened at $156.43 on Monday. The stock has a market capitalization of $70.58 billion, a price-to-earnings ratio of 29.40, a P/E/G ratio of 2.77 and a beta of 0.90. The firm’s 50-day moving average price is $168.10 and its two-hundred day moving average price is $178.61. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis’s dividend payout ratio is currently 37.59%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Institutional Trading of Zoetis

A number of large investors have recently made changes to their positions in ZTS. Norges Bank bought a new stake in shares of Zoetis in the fourth quarter worth about $824,321,000. Mizuho Securities USA LLC grew its position in shares of Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the period. Wellington Management Group LLP increased its stake in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Zoetis during the 4th quarter worth approximately $196,651,000. Finally, Polen Capital Management LLC lifted its stake in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after buying an additional 1,116,541 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.